•
Dec 31, 2020
Milestone Pharmaceuticals Q4 2020 Earnings Report
Milestone Pharmaceuticals' financial position was assessed for the year 2020.
Key Takeaways
Milestone Pharmaceuticals Inc. reported incurring significant operating losses and negative operating cash flows since its inception. As of December 31, 2020, the company had cash, cash equivalents, and short-term investments of $142.3 million and an accumulated deficit of $163.5 million.
The company is focused on developing and commercializing innovative cardiovascular medicines.
Milestone's lead product candidate is etripamil, a novel short-acting calcium channel blocker.
In July 2020, Milestone received $24.8 million in net proceeds from a private placement of pre-funded warrants.
In October 2020, the company concluded an offering of common shares and pre-funded warrants for net proceeds of $48.2 million.